Market Place
Sourcing Support
Theriva Biologics Finalist for Merck KGaA Biotech Grant
31 Oct 2024 //
GLOBENEWSWIRE
Theriva Gets Orphan Designation For VCN-01 In Retinoblastoma
16 Oct 2024 //
GLOBENEWSWIRE
Theriva™ Gets Positive DSMC Review For SYN-004 In HCT Trial
03 Oct 2024 //
GLOBENEWSWIRE
Theriva Biologics Announces Pricing of $2.5 Million Public Offering
26 Sep 2024 //
GLOBENEWSWIRE
Theriva Reaches VIRAGE Trial Enrollment For Pancreatic Cancer
23 Sep 2024 //
GLOBENEWSWIRE
Theriva Biologics Awarded Spanish Government Funding
16 Sep 2024 //
GLOBENEWSWIRE
Theriva Biologics Announces Reverse Stock Split
16 Aug 2024 //
GLOBENEWSWIRE
Theriva Biologics Reports Q2 2024 Results And Operational Highlights
13 Aug 2024 //
GLOBENEWSWIRE
US FDA grants fast track designation to Theriva Biologics’ VCN-01
27 May 2024 //
PHARMABIZ
Theriva Biologics Vcn-01 Fasttrack: For Metastatic Pancreatic Cancer
23 May 2024 //
GLOBENEWSWIRE
Theriva„ Biologics to Participate in the A.G.P. Virtual Healthcare Conference
14 May 2024 //
GLOBENEWSWIRE
Theriva Biologics Q1 2024 Highlights And Financial Results
07 May 2024 //
GLOBENEWSWIRE
Theriva Discusses VIRAGE Trial at ASCO 2024
25 Apr 2024 //
GLOBENEWSWIRE
Theriva Biologics reports positive data ph 1 trial of intravitreal VCN-01
24 Apr 2024 //
PHARMABIZ
Theriva Biologics` VCN-01 Shows Positive Phase 1 Data in Retinoblastoma
23 Apr 2024 //
GLOBENEWSWIRE
Theriva Showing VCN-01 Pancreatic Cancer Combo Potential At ASGCT
22 Apr 2024 //
GLOBENEWSWIRE
Theriva Announces Presentation at the ASGCT 27th Annual Meeting
08 Apr 2024 //
GLOBENEWSWIRE
Theriva„ Biologics Reports Full-Year 2023 Operational Highlights
25 Mar 2024 //
GLOBENEWSWIRE
Theriva Biologics to Host Conference Call & Webcast to Discuss Full Year 2023
19 Mar 2024 //
GLOBENEWSWIRE
Theriva„¢ Biologics to Participate in the BIO-Europe Spring Conference
11 Mar 2024 //
GLOBENEWSWIRE
Theriva to Participate in the B. Riley Securities Annual Oncology Conference
16 Jan 2024 //
GLOBENEWSWIRE
TherivaBiologics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Theriva Biologics to Host Webcast to Discuss Third Quarter 2023 Results
06 Nov 2023 //
GLOBENEWSWIRE
Theriva Biologics to Participate in the BIO-Europe Conference
02 Nov 2023 //
GLOBENEWSWIRE
Theriva Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01
23 Oct 2023 //
GLOBENEWSWIRE
Theriva Biologics Announces Presentation at ESMO Congress 2023
16 Oct 2023 //
GLOBENEWSWIRE
Theriva Biologics to Participate in the Emerging Growth Conference
28 Sep 2023 //
GLOBENEWSWIRE
Theriva Biologics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Theriva Biologics Announces Key Progress in VIRAGE
02 Aug 2023 //
GLOBENEWSWIRE
Theriva Biologics to Discuss Second Quarter 2023 Financial Results
01 Aug 2023 //
GLOBENEWSWIRE
Theriva Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01
27 Jun 2023 //
GLOBENEWSWIRE
Theriva Announces Appointment of Ramon Alemany, Ph.D., to Senior VP
23 May 2023 //
GLOBENEWSWIRE
Theriva Biologics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Theriva Biologics to Host Conference Call & Webcast to Discuss 1Q 2023
04 May 2023 //
GLOBENEWSWIRE
Theriva Announces Presentation of Data from Phase 1b/2a Trial of SYN-004
13 Apr 2023 //
GLOBENEWSWIRE
Theriva Biologics Reports 4Q and Full-Year 2022 Financial Results
30 Mar 2023 //
GLOBENEWSWIRE
Theriva to Reschedule Conference to Discuss Fourth Quarter Financial Results
24 Mar 2023 //
GLOBENEWSWIRE
Theriva Biologics toDiscuss Fourth Quarter and Full-Year 2022 Financial Results
20 Mar 2023 //
GLOBENEWSWIRE
Theriva Announces Presentation of Safety Data from Ph1b/2a Trial of SYN-004
16 Feb 2023 //
GLOBENEWSWIRE
Theriva Announces First Patient Dosed in Phase 2b VIRAGE Trial of VCN-01
18 Jan 2023 //
GLOBENEWSWIRE
Theriva to Participate in B. Riley Securities 3rd Annual Oncology Conference
17 Jan 2023 //
GLOBENEWSWIRE
Theriva Announces Dosing of First Patient in Investigator Sponsored PI of VCN-01
09 Jan 2023 //
GLOBENEWSWIRE
Theriva Biologics to Participate in Upcoming Investor Conferences
01 Dec 2022 //
GLOBENEWSWIRE
Theriva Biologics Reports 3Q 2022 Operational Highlights and Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Theriva to Reschedule Conference Call to Discuss 3Q 2022 Financial Results
10 Nov 2022 //
GLOBENEWSWIRE
Theriva Announces First Patient Dosed in Phase 1b/2a Trial of SYN-004
03 Nov 2022 //
GLOBENEWSWIRE
Theriva Biologics to Host Conference Call and Webcast to Discuss 3Q 2022
03 Nov 2022 //
GLOBENEWSWIRE
Synthetic Biologics rebrands as Theriva Biologics
13 Oct 2022 //
PHARMABIZ
Synthetic completes transformation with new name and cancer-killing virus focus
12 Oct 2022 //
ENDPTS
Synthetic Biologics Announces Presentation at SIOP International Society
30 Sep 2022 //
GLOBENEWSWIRE
Synthetic Biologics Announces +ve Outcome of (DSMC) Review in Ph1b/2a SYN-004
27 Sep 2022 //
GLOBENEWSWIRE
Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Ph1
05 Sep 2022 //
GLOBENEWSWIRE
Synthetic Biologics to Discuss Second Quarter 2022 Financial Results
04 Aug 2022 //
GLOBENEWSWIRE
Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022
04 Aug 2022 //
GLOBENEWSWIRE
Synthetic Bio Announces $3M Private Placement of Convertible Preferred Stock
29 Jul 2022 //
GLOBENEWSWIRE
Synthetic Biologics Announces Reverse Stock Split
15 Jul 2022 //
GLOBENEWSWIRE
Synthetic Biologics Reports First Quarter 2022 Financial Results
16 May 2022 //
GLOBENEWSWIRE
Synthetic Biologics to Discuss First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Synthetic Biologics Announces Formation of Scientific Advisory Board
05 May 2022 //
GLOBENEWSWIRE
